In breast cancer stem cells, it was shown that PRMT5 functions to methylate H3R2, allowing SET1 binding and H3K4 trimethylation at the FOXP1 promoter to activate FOXP1 transcription both in vitro and in vivo. This evidence concerns the gene FOXP1 and breast carcinoma.